nejmc1310849.pdf (502.98 kB)
Download file

Efficacy of vemurafenib in hairy-cell leukemia

Download (502.98 kB)
journal contribution
posted on 01.12.2014, 16:06 by Jesvin Samuel, Salvador Macip, Martin J. S. Dyer
The BR A F V600E mutation is present in nearly all cases of hairy-cell leukemia. 1 This finding has led to the introduction of BRAF inhibitors for the treatment of chemotherapy-re - sistant hairy-cell leukemia, and patients have had a good response to the oral inhibitor vemu - rafenib. 2-4 Constitutive phosphorylation of both extracellular signal-regulated kinase (ERK) and mitogen-activated protein–ERK kinase (MEK) has been considered to be a direct consequence of BRAF activation, with BRAF inhibition result - ing in cell death through suppression of this pathway in hairy-cell leukemia. However, data to support this theory are limited, since most pa - tients present with pancytopenia. [Opening paragraph]

History

Citation

New England Journal of Medicine, 2014, 370 (3), pp. 286-288

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular Medicine

Version

VoR (Version of Record)

Published in

New England Journal of Medicine

Publisher

Massachusetts Medical Society

issn

0028-4793

eissn

1533-4406

Copyright date

2014

Available date

01/12/2014

Publisher version

http://www.nejm.org/doi/pdf/10.1056/NEJMc1310849

Language

en